Eli Lilly (NYSE: LLY) is a top healthcare company with a rich history that goes back to 1876. The Indiana-based business markets its products in 120 countries and has nearly 9,000 employees who are involved with research and development. Its top product is diabetes treatment Trulicity, but with a vast pipeline that features dozens of medicines, that could change.

The company is continuing to grow and it looks like an unstoppable investment, up 30% this year as it has easily outperformed the markets. The following three charts show why there could be even greater gains ahead for this investment, and why it isn't too late to buy shares of Eli Lilly.

Earlier this year, the Food and Drug Administration approved Mounjaro, a type 2 diabetes treatment that could provide Eli Lilly with plenty of long-term growth. Since its launch, the uptake has been significant and volumes are much higher than that of other top diabetes medications, including Trulicity and semaglutide.

Continue reading

Source Fool.com